Risk of injurious road traffic crash after prescription of antidepressants

Journal of Clinical Psychiatry

Volumn 73, Issue 8, 2012, Pages 1088-1094

  Orriols, Ludivine ^a   Queinec, Raphaëlle ^b   Philip, Pierre ^c   Gadegbeku, Blandine ^d,e   Delorme, Bernard ^f   Moore, Nicholas ^g   Suissa, Samy ^h   Lagarde, Emmanuel ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Centre Hospitalier Cadillac   (France)

^c CNRS   (France)

^d UNIVERSITÉ DE LYON   (France)

^e University Lyon   (France)

^f AFSSAPS   (France)

^g Centre of Clinical Investigation Clinical Epidemiology   (France)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPRONIAZID; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE; ZOLPIDEM;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRIVING ABILITY; FEMALE; FRANCE; HUMAN; MALE; PRESCRIPTION; PRIORITY JOURNAL; TRAFFIC ACCIDENT;

EID: 84865735127     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07624     Document Type: Article

References (31)

1. Hindmarch I, Subhan Z, Stoker MJ. The effects of zimeldine and amitriptyline on car driving and psychomotor performance. Acta Psychiatr Scand Suppl. 1983;308:141-146. PubMed
2. Kerr JS, Powell J, Hindmarch I. The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Br J Clin Pharmacol. 1996;42(2):239-241. doi:10.1046/j.1365-2125. 196.39016.x PubMed
3. Ridout F, Meadows R, Johnsen S, et al. A placebo controlled investigation into the effects of paroxetine and mirtazapine on measures related to car driving performance. Hum Psychopharmacol. 2003;18(4):261-269. doi:10.102/hup.494 PubMed
4. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry. 2005;66(4):436-443. doi:10.408/JCP.v6n0405 PubMed
5. Raptopoulos P, McClelland GR, Jackson D. The clinical pharmacology of paroxetine in healthy subjects. Acta Psychiatr Scand Suppl. 1989;80(S350):46-48. doi:10.1/j.160-047.1989.tb07171.x PubMed
6. Robbe HW, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol. 1995;5(1):35-42. doi:10.1016/0924-97X(94)0130-4 PubMed
7. Warrington SJ, Dana-Haeri J, Sinclair AJ. Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand suppl. 1989;80(S350):42-44. doi:10.1/j.160-047.1989.tb07169.x PubMed
8. Kerr JS, Fairweather DB, Hindmarch I. Effects of fluoxetine on psychomotor performance, cognitive function and sleep in depressed patients. Int Clin Psychopharmacol. 1993;8(4):341-344. doi:10.1097/04850-1930840-025 PubMed
9. O'Hanlon JF, Robbe HW, Vermeeren A, et al. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol. 1998;18(3):212-221. doi:10.1097/04714-198060-06 PubMed
10. Wingen M, Ramaekers JG, Schmitt JA. Driving impairment in depressed patients receiving long-term antidepressant treatment. Psychopharmacology (Berl). 2006;188(1):84-91. doi:10.107/s0213-06-0471-7 PubMed
11. Shen J, Moller HJ, Wang X, et al. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry. 2009;70(3):370-377. doi:10.408/JCP.08m04234 PubMed
12. Brunnauer A, Laux G, Geiger E, et al. Antidepressants and driving ability: results from a clinical study. J Clin Psychiatry. 2006;67(11):1776- 1781. doi:10.408/JCP.v67n16 PubMed
13. Brunnauer A, Laux G, David I, et al. The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. J Clin Psychiatry. 2008;69(12):1880-1886. doi:10.408/JCP.v69n1205 PubMed
14. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol. 1992;136(7):873-883. doi:10.1093/aje/136.7.873 PubMed
15. Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology. 1994;5(6):591-598. doi:10.1097/01648-19410-06 PubMed
16. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352(9137):1331-1336. doi:10.1016/S0140-6736(98)04087-2 PubMed
17. Bramness JG, Skurtveit S, Neutel CI, et al. Minor increase in risk of road traffic accidents after prescriptions of antidepressants: a study of population registry data in Norway. J Clin Psychiatry. 2008;69(7):1099-1103. doi:10.408/JCP.v69n0709 PubMed
18. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol. 1995;39(4):397-404. PubMed
19. Orriols L, Delorme B, Gadegbeku B, et al.; CESIR Research Group. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med. 2010;7(11):e1000366. PubMed
20. Trouessin G, Allaert FA. FOIN: a nominative information occultation function. Stud Health Technol Inform. 1997;43 Pt A:196-200. PubMed
21. Robertson MD, Drummer OH. Responsibility analysis: a methodology to study the effects of drugs in driving. Accid Anal Prev. 1994;26(2):243-247. doi:10.1016/01-4575(94)9094-9 PubMed
22. Laumon B, Gadegbeku B, Martin JL, et al; SAM Group. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ. 2005;331(7529):1371. doi:10.136/bmj.38648.617986.1F PubMed
23. Castot A, Delorme B, Medicinal Products and Driving Working Group. Medicinal products and driving: how to assess the risk? Presented at: P2T Congress; April 15-17, 2009; Marseille, France. Abstract 481.
24. AFSSAPS, on behalf of the Medicinal Products and Driving Working Group. Medicinal Products and Driving. http://www.ansm.sante.fr/var/ansm-site/storage/ original/application/e5f2e48d5344bcfef6ca865ac63e7c3d.pdf. Revised March 2009. Accessibility verified June 12, 2012.
25. Arrêté du 8 août 2008 pris pour l'application de l'article R. 5121-139 du code de la santé publique et relatif à l'apposition d'un pictogramme sur le conditionnement extérieur de certains médicaments et produits. http://www.legifrance.gouv.fr/ affichTexte.do?cidTexte=JORFTEXT00001956383 8. Revised October 4, 2008. Accessibility verified June 12, 2012.
26. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144-153. PubMed
27. Bulmash EL, Moller HJ, Kayumov L, et al. Psychomotor disturbance in depression: assessment using a driving simulator paradigm. J Affect Disord. 2006;93(1-3):213-218. doi:10.1016/j.jad.206.01.015 PubMed
28. Baune BT, Miller R, McAfoose J, et al. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2-3):183- 189. doi:10.1016/j.psychres.208.12.01 PubMed
29. Joormann J, Lira Yoon K, Zetsche U. Cognitive inhibition in depression. Appl Prev Psychol. 2007;12(3):128-139. doi:10.1016/j.apsy.207.09.02
30. Honkanen R, Ertama L, Linnoila M, et al. Role of drugs in traffic accidents. BMJ. 1980;281(6251):1309-1312. doi:10.136/bmj.281.6251.1309 PubMed
31. Noize P, Bazin F, Dufouil C, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf. 2009;18(4):310-319. doi:10.102/pds.1717 PubMed